At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 127 enrolled
Drug / intervention
Cabozantinibdrug
Likely dose
Cabozantinib 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
In Brief
A Phase 2 clinical trial evaluating Cabozantinib for Locally Advanced or Metastatic Renal Cell Carcinoma. Completed, enrolled 127 participants across 40 sites in 7 countries.
Detailed Summary
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, France, Germany, Netherlands, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJan 2020
Primary CompletionMay 2023
Study CompletionFeb 2026
TodayJul 2026
First PostedMay 10, 2019
Enrollment StartJan 8, 2020
Primary CompletionMay 11, 2023
Study CompletionFeb 12, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.1 years ago
Interventions
Cabozantinibdrug
Oral tablets of 60mg, 40mg and 20 mg.